USFDA Warning letter to Intas Flags Integrity of Electronic Records, Method Validations, OOS investigations

The USFDA recently issued a warning letter to Intas Pharmaceuticals Limited (Dehradun facility, FEI 3005890633 in March 30, 2026), citing serious lapses in out-of-specification (OOS) investigations, method validation practices, and integrity of electronic records. The site was inspected by FDA investigators Tamil Arasu and Saleem A.Akhtar in September 2025.

OOS Investigation deficiencies

The lapses include inadequate investigation, identification of CAPAs, impact assessment, market actions. A trend of persistent assay failures during stability studies was observed in a product, even after CAPAs and method revisions.

A 12‑month stability failure was investigated and attributed to product behaviour; for investigation the batch was analysed along with previous OOS batches with a revised analytical method and sample preparation procedure with two of the batches again reported OOS. There was no assessment of whether the analytical method itself contributes to result variability. The batch was further recalled, however there was no evaluation of other batches using the same API to determine market impact.

Even after implementing a revised analytical method in 2025, Firm continued to have assay results on the lower end of the specification limits (but within specifications). Lapses were also observed in investigation of further OOS results. An OOS result was invalidated attributing to “solution preparation error” without conclusive supporting evidence and this did not trigger any CAPA plan for analyst training.

Method Validation critical deficiency

The Firm attributed root cause for the OOS to be limitation of the analytical method & incomplete extraction of the active ingredient. However, FDA observed that after revising the method though new assay values are within limit, results are closer to lower end of specification and are still outside the target value; also there was no impact assessment of assay values which were on the higher end of the specification. Most importantly the Firm’s responses did not address why the initial method validation did not identify limitation of the analytical method / incomplete extraction. Also in the investigations there was no review of market complaints and adverse events for low assay batches.

Lapses in data integrity of electronic batch records

It was observed that Quality assurance staff contacted the software vendor for making multiple changes in the electronic batch record after completion of batch. This included change of employee identification number with that of another employee for dispensing activity. These changes were not captured in the audit trail.

Warning letter observed the Firms response to the lapses inadequate as it did not address assessment of communications with other software vendors, deviation documentation, retrospective employee interviews. There was also no explanation why the quality unit failed to log deviation and initiate investigations when discrepancies were noted.

Key Takeaways

• Investigations into deviations /product failures should be comprehensive without prejudice to identify root cause.
• Impact assessment should cover all potentially affected batches. If a 12-month stability failure is being attributed to “product behaviour”, obviously it means other batches could also be impacted.
• When failure investigations conclude product is not impacted (like attributing root cause to other factors like method limitation), completeness of investigation require a review of related past complaints / adverse events and quality events.
• Method limitation root cause for OOS incidents raise concerns on the method validation process. Has something changed post Method validation (“product behaviour”) or Method validation was compromised. Now this will need a comprehensive assessment of all the products, their process / process validation & controls, failure history, method validation status and remediation with significant drain on resources
• Uncontrolled changes to electronic records raises concerns about the entire cGMP computer systems / software qualification and control. The remediation measures would be quite enormous. System-wide evaluation of electronic records; vendor communication (email and others) review to trace all changes / cGMP instructions; enforcement of QMS controls on changes to electronic records in compliance with 21 CFR Part 11 requirements. Further there should be periodic review of the systems / audit trails to ensure that there are no uncontrolled / undocumented changes.

Weak failure investigations and data integrity lapses affect trust in the quality system and its effectiveness. The warning letter underscores the importance of Quality oversight and need for quality systems controls to be embedded into compliance culture.

• USFDA Warning letter – Intas (March 2026)
• USFDA 483 Intas (3005890633)-September 2025